Table 3.
Estimates and 95% confidence intervals from linear mixed-effects models for clinical battery of tests
| Clinical test | MMSE model | CDRSB model | BNT model | NPI model | ||||
|---|---|---|---|---|---|---|---|---|
| Estimatea | P-value | Estimate | P-value | Estimate | P-value | Estimate | P-value | |
| Cross-sectional | ||||||||
| Age at death (5y) | 0.05 (−0.18, 0.29) | 0.66 | −0.02 (−0.21, 0.18) | 0.87 | −0.98 (−1.60, −0.36) | 0.002 | −0.26 (−0.42, −0.09) | 0.002 |
| Male vs female | −0.05 (−0.74, 0.64) | 0.89 | −0.35 (−0.92, 0.22) | 0.23 | 3.07 (1.25, 4.89) | <0.001 | 0.35 (−0.13, 0.82) | 0.16 |
| APOE ε4+ vs ε4− | −0.35 (−1.13, 0.43) | 0.38 | 0.12 (−0.52, 0.76) | 0.71 | −0.51 (−2.57, 1.56) | 0.63 | 0.07 (−0.47, 0.60) | 0.81 |
| Aβ stage (1 level)b | −0.43 (−0.85, −0.004) | 0.048 | 0.48 (0.13, 0.83) | 0.007 | −0.31 (−1.42, 0.81) | 0.59 | 0.47 (0.17, 0.76) | 0.002 |
| Braak NFT stage (1 level) | −0.84 (−1.16, −0.51) | <0.001 | 0.56 (0.29, 0.83) | <0.001 | −1.87 (−2.72, −1.02) | <0.001 | 0.24 (0.01, 0.46) | 0.04 |
| LBD stage (1 level) | −0.14 (−0.46, 0.19) | 0.41 | 0.15 (−0.11, 0.42) | 0.26 | 0.28 (−0.57, 1.14) | 0.52 | 0.31 (0.09, 0.53) | 0.007 |
| TDP-43 stage (1 level) | −1.08 (−1.50, −0.66) | <0.001 | 0.80 (0.46, 1.14) | <0.001 | −2.17 (−3.28, −1.07) | <0.001 | 0.16 (−0.13, 0.45) | 0.28 |
| Longitudinal | ||||||||
| Time to death (1y) | 0.04 (−0.18, 0.26) | 0.71 | 0.05 (−0.20, 0.30) | 0.67 | 0.42 (0.07, 0.77) | 0.02 | 0.15 (−0.07, 0.37) | 0.18 |
| Age at death (5y) | 0.13 (0.08, 0.18) | <0.001 | −0.11 (−0.17, −0.06) | <0.001 | 0.13 (0.05, 0.20) | 0.001 | −0.05 (−0.10, −0.01) | 0.02 |
| Male vs female | 0.0004 (−0.14, 0.14) | >0.99 | −0.12 (−0.27, 0.04) | 0.15 | 0.21 (−0.01, 0.43) | 0.06 | 0.08 (−0.05, 0.21) | 0.25 |
| APOE ε4+ vs ε4− | 0.01 (−0.15, 0.17) | 0.91 | −0.05 (−0.23, 0.13) | 0.59 | −0.13 (−0.38, 0.13) | 0.33 | −0.01 (−0.16, 0.13) | 0.85 |
| Aβ stage (1 level) | −0.02 (−0.11, 0.07) | 0.66 | 0.08 (−0.02, 0.17) | 0.12 | −0.06 (−0.19, 0.08) | 0.40 | 0.03 (−0.06, 0.11) | 0.54 |
| Braak NFT stage (1 level) | −0.19 (−0.26, −0.12) | <0.001 | 0.15 (0.08, 0.23) | <0.001 | −0.31 (−0.42, −0.21) | <0.001 | 0.03 (−0.03, 0.10) | 0.30 |
| LBD stage (1 level) | −0.04 (−0.11, 0.02) | 0.21 | 0.03 (−0.04, 0.11) | 0.36 | −0.00 (−0.10, 0.10) | 0.95 | 0.04 (−0.02, 0.10) | 0.16 |
| TDP-43 stage (1 level) | −0.13 (−0.22, −0.05) | 0.002 | 0.12 (0.03, 0.21) | 0.01 | −0.22 (−0.35, −0.10) | <0.001 | −0.01 (−0.08, 0.07) | 0.89 |
a
Estimates are expressed in terms of 1 point clinical score change
b
Amyloid-beta neuritic plaque score, CERAD C0-3